AskBorsa

Ibnsina Pharma

ISPH
Fiscal year starts in January · currency EGP · latest: Q3 2026
Next results: Fiscal year 2026 — expected around 2 March 2027published last year on 2 March 2026Results calendar ←
10.40EGP−0.38% today1w +0.4%1m −7.7%delayed · 19 November
Net profit · 2025
292million
▼ 52.5% vs 2024
Total assets · 2025
36.21billion
▲ 26.4% vs 2024
Shareholders' equity · 2025
2.78billion
▲ 37.1% vs 2024
Operating cash flow · 2025
−71.06million
▲ 92.3% vs 2024

Key facts

Source: annual statements 2025
  • Ibnsina Pharma's net profit in 2025 was 292 million EGP, down 52.5% from 615 million EGP in 2024.
  • Total assets at the end of 2025 were 36.21 billion EGP, and shareholders' equity 2.78 billion EGP.
  • Operating cash flow in 2025 was negative at 71.06 million EGP.

Ibnsina Pharma's Fiscal year 2026 results are expected around 2 March — we email you the day they land

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

AI summary

Preparing a summary of the latest results…

Annual net profit last 5 years
Net profit
315million
173million
214million
615million
292million
20212022202320242025

Summarised financial statements

Excel · Pro
Swipe the table to see the other years.
Item · EGP20212022202320242025
Income statement
Net profit315 million173 million214 million615 million292 million
Gross profit1.63 billion1.62 billion2.63 billion4.53 billion6.48 billion
Total assets11.28 billion12.86 billion18.55 billion28.64 billion36.21 billion
Total liabilities9.83 billion11.6 billion17.1 billion26.61 billion33.43 billion
Shareholders' equity1.45 billion1.26 billion1.45 billion2.03 billion2.78 billion
Total liabilities and equity11.28 billion12.86 billion18.55 billion28.64 billion36.21 billion
Operating cash flow-340 million614 million126 million-927 million-71.06 million
Investing cash flow-143 million-1.38 billion-280 million-260 million-648 million
Financing cash flow681 million1.09 billion744 million891 million804 million
Net change in cash198 million72.67 million590 million-295 million84.33 million
Sign up free to see the full five years for every period.
Sign up free in seconds
With Google or your email, no password.

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. What does this line mean?

Results by period

One page per period: the figures against the same period a year earlier, and the official report.

Financial reports (19)

Other companies in Health Care & Pharmaceuticals

Ranked by latest annual net profit
All companies in the sector ←